Gary Grohmann
Therapeutic Goods Administration
15 Papers
67 Citations
Gary Grohmann is an academic researcher from Therapeutic Goods Administration. The author has contributed to research in topics: Influenza vaccine & Influenza A virus subtype H5N1. The author has an hindex of 9, co-authored 14 publications. Previous affiliations of Gary Grohmann include University of Sydney.
Chat about Author
Papers
WHO recommendations for the viruses to be used in the 2012 Southern Hemisphere Influenza Vaccine: epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from February to September 2011
Alexander Klimov,Rebecca Garten,Colin A. Russell,Ian G. Barr,Terry G. Besselaar,Rod S. Daniels,Othmar G. Engelhardt,Gary Grohmann,Shigeyuki Itamura,Anne Kelso,John W. McCauley,Takato Odagiri,Derek J. Smith,Masato Tashiro,Xiyan Xu,Richard J. Webby,Dayan Wang,Zhiping Ye,Shu Yuelong,Wenqing Zhang,Nancy J. Cox +20 more
TL;DR: A detailed summary of the antigenic and genetic properties of viruses and additional background data used by WHO experts during development of the recommendations for the 2012 Southern Hemisphere influenza vaccine composition are provided.
73
Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010: Improving influenza vaccine virus selection
William Ampofo,Norman Baylor,Sarah Cobey,Nancy J. Cox,Sharon Daves,Steven Edwards,Neil M. Ferguson,Gary Grohmann,Alan J. Hay,Jacqueline M. Katz,Kornnika Kullabutr,Linda C. Lambert,Roland Levandowski,Akhilesh C. Mishra,Arnold S. Monto,Marilda M. Siqueira,Masato Tashiro,Anthony L. Waddell,Niteen Wairagkar,John Wood,Maria Zambon,Wenqing Zhang +21 more
TL;DR: The expanded and enhanced role of the GISRS, recognition of the continuing threat posed by avian H5N1 and the aftermath of the 2009 H1N1 pandemic provide an opportune time to critically review the process by which influenza vaccine viruses are selected, and to promote greater appreciation by the wider influenza and policy‐making community of the complexity of influenza vaccine virus selection.
66
Influenza Gain-of-Function Experiments: Their Role in Vaccine Virus Recommendation and Pandemic Preparedness
Stacey Schultz-Cherry,Richard J. Webby,Robert G. Webster,Anne Kelso,Ian G. Barr,John W. McCauley,Rod S. Daniels,Dayan Wang,Yuelong Shu,Eri Nobusawa,Shigeyuki Itamura,Masato Tashiro,Yuichi Harada,Shinji Watanabe,Takato Odagiri,Zhiping Ye,Gary Grohmann,Ruth Harvey,Othmar G. Engelhardt,Derek J. Smith,K. Hamilton,Filip Claes,Gwenaelle Dauphin +22 more
TL;DR: Specific examples are provided of how different types of data, including information garnered from GOF studies, have helped to shape the influenza vaccine production process—from selection of candidate vaccine viruses to the manufacture and stockpiling of safe, high-yield prepandemic vaccines for the global community.
29
Pandemic vaccines: promises and pitfalls
TL;DR: It will be 3–6 months into the pandemic before an effective vaccine becomes available, so other control measures will be important in the early stages of a pandemic, so the time to registration of a new product can be minimised.
24
Challenges and successes for the grantees and the Technical Advisory Group of WHO's influenza vaccine technology transfer initiative.
TL;DR: The GAP achieved notable successes with an additional capacity of 338–600 million pandemic vaccine doses being made possible by the programme between 2007 and 2015, and a potential capacity of more than 600 million by 2016/17 with up to one billion doses expected by 2018/19.
14